Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial

Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial

Background To compare intermittent treatment (IT) versus continuous treatment (CT) using cyproterone acetate (CPA) in bone metastatic prostate cancer patients, we conducted an open-label, multicenter randomized trial. Continuous androgen deprivation therapy is the standard treatment in metastatic pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:World journal of urology 2014-10, Vol.32 (5), p.1287-1294
Hauptverfasser: Verhagen, Paul C. M. S., Wildhagen, Mark F., Verkerk, Annet M., Vjaters, Egils, Pagi, Hembo, Kukk, Leonhard, Bratus, Dejan, Fiala, Richard, Bangma, Chris H., Schröder, Fritz H., Mickisch, Gerald H. J.
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Androgen Antagonists - administration & dosage
Bone Neoplasms - drug therapy
Bone Neoplasms - secondary
Cyproterone Acetate - administration & dosage
Humans
Male
Medicine
Medicine & Public Health
Nephrology
Oncology
Original Article
Prostatic Neoplasms - pathology
Urology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background To compare intermittent treatment (IT) versus continuous treatment (CT) using cyproterone acetate (CPA) in bone metastatic prostate cancer patients, we conducted an open-label, multicenter randomized trial. Continuous androgen deprivation therapy is the standard treatment in metastatic prostate cancer. Intermittent treatment might maintain efficacy while toxicity and costs are reduced. Methods Patients received CPA 100 mg tid in the prephase. Patients with a PSA decline of ≥90 % or PSA
ISSN:0724-4983
1433-8726
DOI:10.1007/s00345-013-1206-0